FiercePharma

U.S. FDA Approves Bydureon® Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...
FierceBiotech

Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission

SAN DIEGO and INDIANAPOLIS, Dec. 8 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that ...
Reuters

Amylin Pharms: New storage instructions approved for BYETTA

The co and Eli Lilly (LLY) announces the FDA has approved more convenient patient storage instructions for BYETTA (exenatide) injection. BYETTA Pens can now be kept at a room temperature not to exceed ...
Reuters

Reuters Summit-Novo sees advantages vs Byetta LAR

NEW YORK, Nov 15 (Reuters) - Novo Nordisk A/S said on Thursday it believes its experimental type 2 diabetes treatment will be as effective as the Eli Lilly and Co drug expected to be its main rival ...
FierceBiotech

Chart Review Consistent with Earlier Related Claims Data Analysis of More Than 25,000 BYETTA Patients Accrued Over Three Years

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced final results ...
FiercePharma

US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES

US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES AstraZeneca today announced that the US Food and Drug ...